ClinicalTrials.gg
Not yet recruitingNCT07949669Updated Nov 19, 2026

A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HLX105 in Solid Tumor (Phase I), sponsored by Shanghai Henlius Biotech. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.

02

Conditions studied

  • Solid Tumor (Phase I)
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 134 studies on the registry; 58 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written and comply with study requirements.
  • Aged 18-75 years.
  • or cytologically confirmed advanced or solid tumors following failure of standard treatment, or for which no standard treatment is available.
  • At least one measurable extracranial lesion according to v1.1.
  • performance status of 0-1 and greater than 3 months.
  • Willing to provide adequate archived tumor tissue or undergo a tumor .
  • Adequate organ function;
  • Agreement to comply with protocol-defined requirements during the study and for at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Other within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
  • Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or within protocol-defined .
  • History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
  • History or evidence of interstitial lung disease or other significant pulmonary conditions.
  • Active infections, immunodeficiency, prior organ transplantation, or / infection meeting protocol-defined exclusion criteria.
  • Significant cardiovascular, cerebrovascular, or thromboembolic disease.
  • not meeting protocol-defined stability and eligibility requirements.
  • Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors.

    Drug: HLX105

Interventions

  • DrugHLX105

    HLX105 will be administered as an intravenous(IV) infusion.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.

  2. Maximum tolerated dose(MTD)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Number of participants with adverse events(AEs)

    Time frame: Up to approximately 2 years

  2. Number of participants with serious adverse events(SAEs)

    Time frame: Up to approximately 2 years

  3. Objective response rate(ORR)

    Time frame: Up to approximately 2 years

  4. Disease control rate(DCR)

    Time frame: Up to approximately 2 years

  5. Duration of response (DOR)

    Time frame: Up to approximately 2 years

  6. Progression-free survival(PFS)

    Time frame: Up to approximately 2 years

  7. Overall survival(OS)

    Time frame: Up to approximately 2 years

  8. Cmax

    Maximum serum concentration (Cmax) of HLX105

    Time frame: Up to approximately 2 years

  9. Tmax

    Time to maximum serum concentration (Tmax) of HLX105

    Time frame: Up to approximately 2 years

  10. T1/2

    Half-life (T1/2) of HLX105

    Time frame: Up to approximately 2 years

  11. Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)

    Time frame: Up to approximately 2 years

  12. Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells

    Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment.

    Time frame: Up to approximately 2 years

  13. Change From Baseline in Peripheral Blood Interferon Gamma Concentration

    Time frame: Up to approximately 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 19, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949669
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Waihan Ho
Contact
Waihan_Ho@henlius.com
+65-96253244

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion